This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer
In this promising investigation, investigators found that C4d, a degradation product of complement activation, assessed in bronchoalveolar lavage and plasma, predicts the presence of lung cancer compared with non-cancer patients. They found a shorter survival in patients with high levels in the plasma. Plasma C4d levels were reduced after surgical resections, which means C4d may be useful as a marker of recurrence after resection.